Global therapeutic pipeline for non-oncology orphan drug programs by company 2019
This graph shows the number of orphan designated drugs currently being developed by emerging therapeutic companies in the U.S., as of April 2019. As of this time, of the 612 non-oncologic orphan programs being developed, almost half were in Phase II of development.